Sign In
Buy IDYA
$28.40
+0.530 (+1.90%)
At Close: Jun 03, 2026
IDEAYA Announces Pricing of Public Offering
10:26pm, Tuesday, 09'th Jul 2024
SOUTH SAN FRANCISCO, Calif. , July 9, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warran
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:08pm, Tuesday, 09'th Jul 2024
SOUTH SAN FRANCISCO, Calif. , July 9, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $200.0 million of shares of its common stock a
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
02:52pm, Tuesday, 09'th Jul 2024
IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.
Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?
07:56am, Tuesday, 09'th Jul 2024
IDEAYA Biosciences (IDYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea
IDEAYA Biosciences Soars on Cancer Drug Study Results
01:05pm, Monday, 08'th Jul 2024
Shares of IDEAYA Biosciences (IDYA) took off in intraday trading Monday after the biotech announced positive results in a mid-stage study of its treatment for certain bladder and small-cell lung cance
IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer
12:31pm, Monday, 08'th Jul 2024
Monday, IDEAYA Biosciences Inc IDYA released clinical data for the IDE397 Phase 2 monotherapy expansion dose in methylthioadenosine phosphorylase-deletion urothelial and non-small cell lung cancer pat
Why Ideaya Biosciences Just Made Its Most Bullish Move Since March
09:14am, Monday, 08'th Jul 2024
Ideaya Biosciences presented promising results Monday for a drug that tackles hard-to-treat cancers. The biotech stock surged.
~39% Overall Response Rate (ORR): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out of 18 evaluable MTAP-deletion urothelial and NSCLC patients ~94% Disease Control Rate (DCR): 1 CR and 6 PRs
SOUTH SAN FRANCISCO, Calif. , July 5, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeu
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06:00am, Friday, 28'th Jun 2024
SOUTH SAN FRANCISCO, Calif. , June 28, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted thera
First-Patient-In (FPI) for Phase 1 combination treatment with IDE397, IDEAYA's MAT2A inhibitor, and Trodelvy®, Gilead's Trop-2 directed antibody-drug conjugate (ADC) The global Phase 1 clinical trial
Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung and bladder cancer patients in H2 2024, including RECIST 1.1 clinical efficacy waterfall, swim
75% eye preservation rate (9 of 12 enucleation patients) ~67% (8 of 12 enucleation patients) observed greater than 30% tumor shrinkage and median tumor shrinkage of 47% by volume change after 6 mont
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06:00am, Friday, 31'st May 2024
SOUTH SAN FRANCISCO , May 31, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,
IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
06:00am, Wednesday, 29'th May 2024
SOUTH SAN FRANCISCO, Calif. , May 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap
